Ülke: Birleşik Krallık
Dil: İngilizce
Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)
Rabies virus inactivated
Sanofi Pasteur
J07BG01
Rabies virus inactivated
Powder and solvent for suspension for injection
Intramuscular
No Controlled Drug Status
Valid as a prescribable product
BNF: 14040000; GTIN: 5015973061014
Page 1 of 6 PACKAGE LEAFLET: INFORMATION FOR THE USER RABIES VACCINE BP ≥ 2.5 IU/ML POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD ARE VACCINATED. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, nurse or pharmacist. - This vaccine has been prescribed for you. Do not pass it on to others. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist. IN THIS LEAFLET : 1. What Rabies Vaccine BP is and what it is used for 2. Before you are given Rabies Vaccine BP 3. How Rabies Vaccine BP is given 4. Possible side effects 5. How to store Rabies Vaccine BP 6. Further information 1. WHAT RABIES VACCINE BP IS AND WHAT IT IS USED FOR Rabies Vaccine BP is one of a general group of medicines called vaccines. Vaccines are used to protect against infectious diseases. This vaccine helps to protect adults and children against rabies. Rabies Vaccine BP can be used in two ways: • Vaccinating you before you come into contact with rabies virus. • Vaccinating you after you have come into contact with rabies virus. Rabies Vaccine BP is a preparation containing very small amounts of a modified form of the virus that causes rabies. When an injection of Rabies Vaccine BP is given, the body's natural defences will produce protection against R abies. 2. BEFORE YOU ARE GIVEN RABIES VACCINE BP To make sure that this vaccine is suitable for you or your child, it is important to tell the doctor, nurse or pharmacist if any points below apply. If there is anything you do not understand, ask your doctor, nurse or pharmacist to explain. DO NOT HAVE RABIES VACCINE BP IF YOU OR YOUR CHILD IS: • allergic (hypersensitive) to Rabies Vaccine BP or any of its ingredients (see section 6). • allergic (hypersensitive) to neomycin or betapropiolactone because these are used during vaccine production and may be present in the vaccine in small a Belgenin tamamını okuyun
OBJECT 1 RABIES VACCINE BP Summary of Product Characteristics Updated 28-Mar-2018 | Sanofi Pasteur 1. Name of the medicinal product Rabies Vaccine BP ≥ 2.5 IU/ml, Powder and solvent for suspension for injection 2. Qualitative and quantitative composition After reconstitution, 1 dose (1ml) contains: Rabies virus* (inactivated, strain PM/WI 38 1503-3M)……..≥2.5 IU *produced in human diploid MRC-5 cells For a full list of excipients, see section 6.1 3. Pharmaceutical form Powder and solvent for suspension for injection The powder is pinkish beige to orangey yellow. The solvent is a clear, colourless solution. 4. Clinical particulars 4.1 Therapeutic indications For prophylactic immunisation against rabies. Treatment of patients following suspected rabies contact. 4.2 Posology and method of administration Administer by intramuscular injection. The vaccine should be administered into the deltoid region. For instructions on the reconstitution of the vaccine before administration, see section 6.6. _Pre-exposure prophylaxis_ One injection of 1 millilitre given each day on days 0, 7 and 28. The earliest day that the 3 rd dose can be given to achieve effective immune status is day 21. For those at regular and continuing risk, a single reinforcing dose of vaccine should be given at 1 year after the primary course has been completed. Further doses should be given at three- to five-year intervals thereafter. For travellers at intermittent risk of exposure, booster doses may be given in line with official recommendations. The need for serology testing to detect the presence of rabies virus-neutralising antibodies (≥0.5 IU/ml) should be assessed and conducted, if appropriate, in accordance with official recommendations. _Post-exposure prophylaxis_ Post-exposure treatment should begin as soon as possible after the suspected contact. Immediate wound toilet is important to reduce the risk of infection, followed by the administration of the vaccine and passive immunisation if indicated; this should be carried out in accorda Belgenin tamamını okuyun